Checkpoint Inhibitor Refractory Cancer Market Projected to Reach $133.96 Billion by 2035

The global market for checkpoint inhibitor refractory cancer is projected to reach $133.96 billion by 2035, a significant increase from an estimated $42.63 billion in 2025. According to a report by Credence Research Inc., this growth represents a compound annual growth rate (CAGR) of 12.13% between 2025 and 2035.

North America dominated the market, holding a 47.0% share in 2025. The Asia Pacific region is expected to experience the fastest growth, with a projected CAGR of 13.77%. These figures are estimates from Credence Research.

PD-1 inhibitors accounted for the largest segment within therapy types, representing 66.0% of the market value in 2025. Non-small cell lung cancer was the leading application, comprising 38.0% of application revenue. Hospital pharmacies were the primary distribution channel, capturing 78.0% of the market.

The market's expansion is attributed to the growing need for effective treatments for patients whose cancer is resistant to or has progressed after checkpoint inhibitor therapy. Advancements in immunotherapies and combination treatments are addressing these unmet medical needs.